Literature DB >> 33730756

Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy.

Bram Verstockt1,2, Nurulamin M Noor3,4, Urko M Marigorta5,6, Polychronis Pavlidis7,8, Parakkal Deepak9, Ryan C Ungaro10.   

Abstract

Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes, Crohn's disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical variations. Hence, we should no longer approach all IBD patients similarly, but rather aim to rethink clinical classifications and modify treatment algorithms to usher in a new era of precision medicine in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers, shed light on key questions in biomarker development, propose best practices in IBD biomarker development [including trial design], and discuss the potential for multi-omic data integration to help drive further advances to make precision medicine a reality in IBD.
© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Precision medicine; disease outcome; disease prognosis; inflammatory bowel diseases; personalised medicine; response to therapy

Mesh：

Substances：

Year:  2021        PMID： 33730756      PMCID： PMC8681673          DOI： 10.1093/ecco-jcc/jjab050

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


  107 in total

1.  A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.

Authors:  Thomas Billiet; Konstantinos Papamichael; Magali de Bruyn; Bram Verstockt; Isabelle Cleynen; Fred Princen; Sharat Singh; Marc Ferrante; Gert Van Assche; Severine Vermeire
Journal:  J Crohns Colitis       Date:  2015-09-07       Impact factor: 9.071

2.  International Conference on Harmonisation; Guidance on E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions; availability. Notice.

Authors: 
Journal:  Fed Regist       Date:  2011-08-11

Review 3.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.

Authors:  Joseph D Feuerstein; Geoffrey C Nguyen; Sonia S Kupfer; Yngve Falck-Ytter; Siddharth Singh
Journal:  Gastroenterology       Date:  2017-08-03       Impact factor: 22.682

4.  Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease.

Authors:  Benjamin Pariente; Jean-Yves Mary; Silvio Danese; Yehuda Chowers; Peter De Cruz; Geert D'Haens; Edward V Loftus; Edouard Louis; Julian Panés; Jürgen Schölmerich; Stefan Schreiber; Maurizio Vecchi; Julien Branche; David Bruining; Gionata Fiorino; Matthias Herzog; Michael A Kamm; Amir Klein; Maïté Lewin; Paul Meunier; Ingrid Ordas; Ulrike Strauch; Gian-Eugenio Tontini; Anne-Marie Zagdanski; Cristiana Bonifacio; Jordi Rimola; Maria Nachury; Christophe Leroy; William Sandborn; Jean-Frédéric Colombel; Jacques Cosnes
Journal:  Gastroenterology       Date:  2014-09-21       Impact factor: 22.682

5.  Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD).

Authors:  Sare Verstockt; Bram Verstockt; Séverine Vermeire
Journal:  Expert Opin Ther Targets       Date:  2019-10-15       Impact factor: 6.902

Review 6.  Replicability and Prediction: Lessons and Challenges from GWAS.

Authors:  Urko M Marigorta; Juan Antonio Rodríguez; Greg Gibson; Arcadi Navarro
Journal:  Trends Genet       Date:  2018-04-30       Impact factor: 11.639

7.  Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.

Authors:  William J Sandborn; Severine Vermeire; Helen Tyrrell; Azra Hassanali; Stuart Lacey; Swati Tole; Amanda R Tatro
Journal:  Adv Ther       Date:  2020-05-22       Impact factor: 3.845

8.  The Integrative Human Microbiome Project.

Authors: 
Journal:  Nature       Date:  2019-05-29       Impact factor: 49.962

9.  A blood-based prognostic biomarker in IBD.

Authors:  Daniele Biasci; James C Lee; Nurulamin M Noor; Diana R Pombal; Monica Hou; Nina Lewis; Tariq Ahmad; Ailsa Hart; Miles Parkes; Eoin F McKinney; Paul A Lyons; Kenneth G C Smith
Journal:  Gut       Date:  2019-04-27       Impact factor: 23.059

10.  Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD.

Authors:  Renaud Gaujoux; Elina Starosvetsky; Naama Maimon; Yehuda Chowers; Purvesh Khatri; Shai S Shen-Orr; Francesco Vallania; Haggai Bar-Yoseph; Sigal Pressman; Roni Weisshof; Idan Goren; Keren Rabinowitz; Matti Waterman; Henit Yanai; Iris Dotan; Edmond Sabo
Journal:  Gut       Date:  2018-04-04       Impact factor: 23.059
View more
  8 in total

Review 1.  Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease.

Authors:  Bram Verstockt; Stefania Vetrano; Azucena Salas; Shadi Nayeri; Marjolijn Duijvestein; Niels Vande Casteele
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-02-14       Impact factor: 73.082

Review 2.  Unmet needs in inflammatory bowel disease.

Authors:  Joana Revés; Ryan C Ungaro; Joana Torres
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-11-30

Review 3.  Network Biology Approaches to Achieve Precision Medicine in Inflammatory Bowel Disease.

Authors:  John P Thomas; Dezso Modos; Tamas Korcsmaros; Johanne Brooks-Warburton
Journal:  Front Genet       Date:  2021-10-21       Impact factor: 4.599

Review 4.  Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises.

Authors:  Dahham Alsoud; Séverine Vermeire; Bram Verstockt
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-01-26

Review 5.  Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD.

Authors:  Nurulamin M Noor; Paula Sousa; Stéphane Paul; Xavier Roblin
Journal:  Inflamm Bowel Dis       Date:  2022-08-01       Impact factor: 7.290

6.  Machine learning-based detection of immune-mediated diseases from genome-wide cell-free DNA sequencing datasets.

Authors:  Huiwen Che; Tatjana Jatsenko; Lore Lannoo; Kate Stanley; Luc Dehaspe; Leen Vancoillie; Nathalie Brison; Ilse Parijs; Kris Van Den Bogaert; Koenraad Devriendt; Sabien Severi; Ellen De Langhe; Severine Vermeire; Bram Verstockt; Kristel Van Calsteren; Joris Robert Vermeesch
Journal:  NPJ Genom Med       Date:  2022-09-14       Impact factor: 6.083

7.  Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy.

Authors:  Polychronis Pavlidis; Anastasia Tsakmaki; Eirini Pantazi; Katherine Li; Domenico Cozzetto; Jonathan Digby-Bell; Feifei Yang; Jonathan W Lo; Elena Alberts; Ana Caroline Costa Sa; Umar Niazi; Joshua Friedman; Anna K Long; Yuchun Ding; Christopher D Carey; Christopher Lamb; Mansoor Saqi; Matthew Madgwick; Leila Gul; Agatha Treveil; Tamas Korcsmaros; Thomas T Macdonald; Graham M Lord; Gavin Bewick; Nick Powell
Journal:  Nat Commun       Date:  2022-10-03       Impact factor: 17.694

Review 8.  The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges.

Authors:  Daniele Noviello; Riccardo Mager; Giulia Roda; Riccardo G Borroni; Gionata Fiorino; Stefania Vetrano
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.